Brainstorm Cell Therapeutics | BCLI - Cash And Equivalent


Brainstorm Cell Therapeutics reported $22K in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Biogen USD 1.28B 2.1B Jun/2026
Brainstorm Cell Therapeutics USD 22K 7K Jun/2026
Cipla INR 10.18B 2.22B Mar/2026
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 12.43M 78.16M Mar/2026
CSL USD 2.16B 633M Jun/2025
Cytokinetics USD 255.27M 125.43M Jun/2026
Gilead Sciences USD 7.63B 64M Mar/2026
Grifols EUR 979.78M 334.84M Dec/2024
Halozyme Therapeutics USD 163.14M 146.61M Jun/2026
Mesoblast USD 129.57M 31.58M Dec/2025